Acquired Inhibitors of coagulation factors: Part I-acquired hemophilia a

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 5, 2012, Pages 433-446

  Coppola, Antonio ^a   Favaloro, Emmanuel J ^b   Tufano, Antonella ^a   Di Minno, Matteo N D ^a   Cerbone, Anna Maria ^a   Franchini, Massimo ^c  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^b WESTMEAD HOSPITAL   (Australia)

^c CARLO POMA HOSPITAL   (Italy)

Author keywords

acquired hemophilia A; autoantibodies; bleeding; inhibitors

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AZATHIOPRINE; BLOOD CLOTTING INHIBITOR; CYCLOPHOSPHAMIDE; DESMOPRESSIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; STEROID; AUTOANTIBODY; BLOOD CLOTTING FACTOR;

ACQUIRED HEMOPHILIA A; ARTICLE; COHORT ANALYSIS; COMORBIDITY; COMPRESSION STOCKING; COMPUTER ASSISTED TOMOGRAPHY; CROSS REACTION; DISEASE REGISTRY; HEMARTHROSIS; HEMOPHILIA A; HUMAN; IMMUNOADSORPTION; MORTALITY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; UNITED KINGDOM; BLEEDING; BLOOD; BLOOD CLOTTING TEST; DRUG ANTAGONISM; IMMUNOLOGY; REVIEW;

AUTOANTIBODIES; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; HEMOPHILIA A; HEMORRHAGE; HUMANS;

EID: 84872962482     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1315757     Document Type: Article

References (109)

1. Bouvry P., Recloux P. Acquired hemophilia. Haematologica: 1994; 79 6 550 556
2. Delgado J., Jimenez-Yuste V., Hernandez-Navarro F., Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol: 2003; 121 1 21 35 (Pubitemid 36461264)
3. Green D., Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost: 1981; 45 3 200 203 (Pubitemid 11081028)
4. Collins P. W., Hirsch S., Baglin T. P., et al. UK Haemophilia Centre Doctors' Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood: 2007; 109 5 1870 1877 (Pubitemid 46348182)
5. Baudo F., de Cataldo F., Gaidano G.; Italian registry of acquired hemophilia. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia. Haematologica: 2004; 89 6 759 761
6. Ma A., Kessler C. M., Gut R. Z., Cooper D. L. Treatment of acquired haemophilia with recombinant factor VIIa (rFVIIa): an updated analysis from the hemophilia and thrombosis research society (HTRS) registry. J Thromb Haemost: 2011; 9 02 476 (abstract P-TU-532)
7. Borg I-Y, Negrier C., Durieu I., et al. Prospective clinical and biological evaluation of antihemorrhagic treatment with factor eight inhibitor bypassing activity in acquired hemophilia, FEIBHAC Study. J Thromb Haemost: 2011; 9 02 938 939 (abstract P-TH-545)
8. Knoebl P., Marco P., Baudo F., et al. EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost: 2012; 10 4 622 631
9. Huth-Kühne A., Baudo F., Collins P., et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica: 2009; 94 4 566 575
10. Franchini M., Lippi G., Favaloro E. J. Acquired inhibitors of coagulation factors: part II. Semin Thromb Haemost: 2012; 38 5 447 453
11. Tufano A., Coppola A., Guida A., et al. Acquired haemophilia a in the elderly: case reports. Curr Gerontol Geriatr Res: 2010; 2010 927503
12. Collins P., Macartney N., Davies R., Lees S., Giddings J., Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol: 2004; 124 1 86 90 (Pubitemid 38021627)
13. Moraca R. J., Ragni M. V. Acquired anti-FVIII inhibitors in children. Haemophilia: 2002; 8 1 28 32 (Pubitemid 34257916)
14. Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey. Am J Hematol: 1998; 59 1 1 4 (Pubitemid 28394998)
15. Hauser I., Schneider B., Lechner K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost: 1995; 73 1 1 5
16. Baudo F., de Cataldo F.; Italian Association of Haemophilia Centres (AICE): Register of acquired factor VIII inhibitors (RIIA). Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Registry relevant to clinical practice. BJOG: 2003; 110 311 314 (Pubitemid 36298918)
17. Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol: 2006; 81 10 768 773 (Pubitemid 44536745)
18. Kesley P. R., Leyland M. J. Acquired inhibitor to human factor VIII associated with paraproteinemia and subsequent development of chronic lymphocytic leukemia. Br Med J (Clin Res Ed): 1982; 285 6336 174 175 (Pubitemid 12079073)
19. Meiklejohn D. J., Watson H. G. Acquired haemophilia in association with organ-specific autoimmune disease. Haemophilia: 2001; 7 5 523 525 (Pubitemid 32923262)
20. Coppola A., Tufano A., Di Capua M., Franchini M. Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost: 2011; 37 8 929 945
21. Morrison A. E., Ludlam C. A., Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood: 1993; 81 6 1513 1520 (Pubitemid 23083829)
22. Bossi P., Cabane J., Ninet J., et al. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med: 1998; 105 5 400 408 (Pubitemid 28536225)
23. Yee T. T., Taher A., Pasi K. J., Lee C. A. A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period. Clin Lab Haematol: 2000; 22 5 275 278 (Pubitemid 32047101)
24. Tay L., Duncan E., Singhal D., et al. Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia. Semin Thromb Hemost: 2009; 35 8 769 777
25. Hauser I., Lechner K. Solid tumors and factor VIII antibodies. Thromb Haemost: 1999; 82 3 1005 1007 (Pubitemid 29419708)
26. Sallah S., Wan J. Y. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer: 2001; 91 6 1067 1074 (Pubitemid 32295411)
27. Sallah S., Nguyen N. P., Abdallah J. M., Hanrahan L. R. Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med: 2000; 124 5 730 734 (Pubitemid 30321878)
28. Franchini M., Targher G., Manzato F., Lippi G. Acquired factor VIII inhibitors in oncohematology: a systematic review. Crit Rev Oncol Hematol: 2008; 66 3 194 199
29. Trotta F., Bajocchi G., La Corte R., Moratelli S., Sun L. Y. Long-lasting remission and successful treatment of acquired factor VIII inhibitors using cyclophosphamide in a patient with systemic lupus erythematosus. Rheumatology (Oxford): 1999; 38 10 1007 1009 (Pubitemid 29505085)
30. Soriano R. M., Matthews J. M., Guerado-Parra E. Acquired haemophilia and rheumatoid arthritis. Br J Rheumatol: 1987; 26 5 381 383 (Pubitemid 17146399)
31. Vignes S., Le Moing V., Meekel P., Papo T., Wechsler B., Godeau P. Acquired hemophilia: a rare complication of Sjögren's syndrome. Clin Exp Rheumatol: 1996; 14 5 559 560 (Pubitemid 26335481)
32. Hoyle C., Ludlam C. A. Acquired factor VIII inhibitor associated with multiple sclerosis, successfully treated with porcine factor VIII. Thromb Haemost: 1987; 57 2 233
33. Seidler C. W., Mills L. E., Flowers M. E., Sullivan K. M. Spontaneous factor VIII inhibitor occurring in association with chronic graft-versus-host disease. Am J Hematol: 1994; 45 3 240 243 (Pubitemid 24053438)
34. Sievert R., Goldstein M. L., Surks M. I. Graves' disease and autoimmune factor VIII deficiency. Thyroid: 1996; 6 3 245 247 (Pubitemid 26279419)
35. Stewart A. J., Manson L. M., Dasani H., et al. Acquired haemophilia in recipients of depot thioxanthenes. Haemophilia: 2000; 6 6 709 712
36. Sallah S., Wan J. Y. Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine. Thromb Haemost: 2001; 86 4 1119 1121 (Pubitemid 32975845)
37. Regina S., Colombat P., Fimbel B., Guerois C., Gruel Y. Acquired inhibitor to factor VIII in a patient with Hodgkin's disease following treatment with interferon-alpha. Haemophilia: 2001; 7 5 526 527 (Pubitemid 32923263)
38. Mauser-Bunschoten E. P., Damen M., Reesink H. W., Roosendaal G., Chamuleau R. A., van den Berg H. M. Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C. Ann Intern Med: 1996; 125 4 297 299 (Pubitemid 126449275)
39. Capra F., Nicolini N., Franchini M. Is the periodic repetition of a coagulation check necessary during anti-hepatitis C virus therapy? Gut: 2006; 55 6 902 (Pubitemid 43764571)
40. Tiplady C. W., Hamilton P. J., Galloway M. J. Acquired haemophilia complicating the remission of a patient with high grade non-Hodgkin's lymphoma treated by fludarabine. Clin Lab Haematol: 2000; 22 3 163 165 (Pubitemid 30625574)
41. Franchini M., Capra F., Nicolini N., et al. Drug-induced anti-factor VIII antibodies: a systematic review. Med Sci Monit: 2007; 13 4 RA55 RA61 (Pubitemid 46557763)
42. Dentale N., Fulgaro C., Guerra L., Fasulo G., Mazzetti M., Fabbri C. Acquisition of factor VIII inhibitor after acute hepatitis C virus infection. Blood: 1997; 90 8 3233 3234 (Pubitemid 27444222)
43. Michiels J. J. Acquired hemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment. Clin Appl Thromb Hemost: 2000; 6 2 82 86 (Pubitemid 30230629)
44. Santoro R. C., Prejanò S. Postpartum-acquired haemophilia A: a description of three cases and literature review. Blood Coagul Fibrinolysis: 2009; 20 6 461 465
45. Coller B. S., Hultin M. B., Hoyer L. W., et al. Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis. Blood: 1981; 58 3 619 624 (Pubitemid 11002767)
46. Ries M., Wölfel D., Maier-Brandt B. Severe intracranial hemorrhage in a newborn infant with transplacental transfer of an acquired factor VII:C inhibitor. J Pediatr: 1995; 127 4 649 650
47. Franchini M., Capra F., Capelli C., de Maria E., Lippi G., Gandini G. Clinical efficacy of recombinant activated factor VII (rFVIIa) during acute bleeding episode and surgery in a patient with acquired hemophilia A with high inhibitor titer. Haematologica: 2001; 86 4 E12
48. Hultin M. B. Acquired inhibitors in malignant and nonmalignant disease states. Am J Med: 1991; 91 5A 9S 13S
49. Lottenberg R., Kentro T. B., Kitchens C. S. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med: 1987; 147 6 1077 1081 (Pubitemid 17113272)
50. Favaloro E. J., Bonar R., Duncan E., et al. RCPA QAP in Haematology Haemostasis Committee. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost: 2006; 96 1 73 78 (Pubitemid 44160873)
51. Favaloro E. J., Bonar R., Duncan E., et al. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology: 2007; 39 5 504 511 (Pubitemid 47454494)
52. Ewing N. P., Kasper C. K. In vitro detection of mild inhibitors to factor VIII in hemophilia. Am J Clin Pathol: 1982; 77 6 749 752 (Pubitemid 12073176)
53. Kershaw G., Jayakodi D., Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Semin Thromb Hemost: 2009; 35 8 760 768
54. Kershaw G., Favaloro E. J. Laboratory identification of factor inhibitors: an update. Pathology: 2012; 44 4 293 302
55. Verbruggen B., Novakova I., Wessels H., Boezeman J., van den Berg M., Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost: 1995; 73 2 247 251
56. Collins P., Baudo F., Huth-Kühne A., et al. Consensus recommendations for the diagnosis and treatment of acquired haemophilia A. BMC Res Notes: 2010; 3 161
57. Cohen A. J., Kessler C. M. Acquired inhibitors. Baillieres Clin Haematol: 1996; 9 2 331 354 (Pubitemid 26185952)
58. Reding M. T. Immunological aspects of inhibitor development. Haemophilia: 2006; 12 06 30 35, discussion 35-36
59. Bray G. L., Kroner B. L., Arkin S., et al. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol: 1993; 42 4 375 379 (Pubitemid 23104809)
60. Reding M. T., Lei S., Lei H., Green D., Gill J., Conti-Fine B. M. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost: 2002; 88 4 568 575 (Pubitemid 35173996)
61. Reding M. T., Okita D. K., Diethelm-Okita B. M., Anderson T. A., Conti-Fine B. M. Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost: 2003; 1 8 1777 1784
62. Oldenburg J., Zeitler H., Pavlova A. Genetic markers in acquired haemophilia. Haemophilia: 2010; 16 03 41 45
63. Kasper C. K. Complications of hemophilia A treatment: factor VIII inhibitors. Ann N Y Acad Sci: 1991; 614 97 105
64. Franchini M., Lippi G. Acquired factor VIII inhibitors. Blood: 2008; 112 2 250 255
65. Toschi V., Baudo F. Diagnosis, laboratory aspects and management of acquired hemophilia A. Intern Emerg Med: 2010; 5 4 325 333
66. Collins P. W. Management of acquired haemophilia A. J Thromb Haemost: 2011; 9 01 226 235
67. Paisley S., Wight J., Currie E., Knight C. The management of inhibitors in haemophilia A: introduction and systematic review of current practice. Haemophilia: 2003; 9 4 405 417 (Pubitemid 36874390)
68. Hay C. R., Brown S., Collins P. W., Keeling D. M., Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol: 2006; 133 6 591 605 (Pubitemid 43742773)
69. Hay C. RM, Negrier C., Ludlam C. A. The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost: 1997; 78 6 1463 1467 (Pubitemid 27519390)
70. Sumner M. J., Geldziler B. D., Pedersen M., Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia: 2007; 13 5 451 461 (Pubitemid 47337982)
71. Knoebl P., Baudo F., Collins P. W., et al. Management of Bleeding In Acquired Hemophilia: Results of the European Acquired Hemophilia Registry (EACH2). Blood: 2010; 116 21 716
72. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia: 2004; 10 2 169 173 (Pubitemid 38312644)
73. Goudemand J. Treatment of bleeding episodes occurring in patients with acquired haemophilia with FEIBA: the French experience. Haemophilia: 2004; 10 03 abstract PO14
74. Dehmel H., Werwitzke S., Trummer A., Ganser A., Tiede A. Thrombelastographic monitoring of recombinant factor VIIa in acquired haemophilia. Haemophilia: 2008; 14 4 736 742 (Pubitemid 352016029)
75. Sorensen B., Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia: 2005; 11 01 1 6 (Pubitemid 41631603)
76. Sorensen B., Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost: 2004; 2 1 102 110 (Pubitemid 40185626)
77. Váradi K., Negrier C., Berntorp E., et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost: 2003; 1 11 2374 2380
78. Aledort L. M. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia: 2008; 14 1 39 43
79. ®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience. Haemophilia: 2012; 10.1111/j.1365-2516.2012.02748.x
80. Aledort L. M. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost: 2004; 2 10 1700 1708 (Pubitemid 40192708)
81. Ehrlich H. J., Henzl M. J., Gomperts E. D. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia: 2002; 8 2 83 90 (Pubitemid 35238060)
82. Franchini M., Lippi G. Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost: 2010; 36 5 485 492
83. Mahlangu J. N., Coetzee M. J., Laffan M., et al. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost: 2012; 10 5 773 780
84. Schulte S. Pioneering designs for recombinant coagulation factors. Thromb Res: 2011; 128 01 S9 S12
85. Franchini M., Lippi G. The use of desmopressin in acquired haemophilia A: a systematic review. Blood Transfus: 2011; 9 4 377 382
86. Toschi V. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII. Curr Opin Mol Ther: 2010; 12 5 617 625
87. Négrier C., Dechavanne M., Alfonsi F., Tremisi P. J. Successful treatment of acquired factor VIII antibody by extracorporeal immunoadsorption. Acta Haematol: 1991; 85 2 107 110
88. Jansen M., Schmaldienst S., Banyai S., et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol: 2001; 112 1 91 97 (Pubitemid 32151155)
89. Franchini M., Sassi M., Dell'Anna P., et al. Extracorporeal immunoadsorption for the treatment of coagulation inhibitors. Semin Thromb Hemost: 2009; 35 1 76 80
90. Zeitler H., Ulrich-Merzenich G., Hess L., et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood: 2005; 105 6 2287 2293 (Pubitemid 40387021)
91. Spero J. A., Lewis J. H., Hasiba U. Corticosteroid therapy for acquired F VIII:C inhibitors. Br J Haematol: 1981; 48 4 635 642 (Pubitemid 11051271)
92. Lian E. C., Larcada A. F., Chiu A. Y. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med: 1989; 110 10 774 778 (Pubitemid 19128994)
93. Green D., Rademaker A. W., Briët E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost: 1993; 70 5 753 757 (Pubitemid 23339447)
94. Shaffer L. G., Phillips M. D. Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann Intern Med: 1997; 127 3 206 209 (Pubitemid 27332539)
95. Schulman S., Langevitz P., Livneh A., Mortinowitz U., Seligsohn U., Varon D. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost: 1996; 76 3 344 346 (Pubitemid 26373525)
96. Petrovic M., Derom E., Baele G. Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies. Haematologica: 2000; 85 8 895 896
97. Pardos-Gea J., Ordi-Ros J., Altisent C., Balada E., Pérez- López J., Vilardell M. Acquired haemophilia A: successful treatment with immunosuppression, methylprednisolone pulses and oral cyclosporin. Thromb Haemost: 2006; 95 4 735 737
98. Collins P. W., Baudo F., Knoebl P., et al. Inhibitor Eradication In Acquired Haemophilia A: Final Results of European Acquired Haemophilia Registry (EACH2). Blood: 2010; 116 21 abstract 715
99. Nicolaides A. N., Breddin H. K., Carpenter P., et al. European Genetics Foundation; Cardiovascular Disease Educational and Research Trust; International Union of Angiology; Mediterranean League on Thromboembolism. Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol: 2005; 24 1 1 26 (Pubitemid 43933045)
100. Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood: 2001; 98 4 952 957
101. Wiestner A., Cho H. J., Asch A. S., et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood: 2002; 100 9 3426 3428 (Pubitemid 35217098)
102. Onitilo A. A., Skorupa A., Lal A., et al. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost: 2006; 96 1 84 87 (Pubitemid 44160875)
103. Field J. J., Fenske T. S., Blinder M. A. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy. Haemophilia: 2007; 13 1 46 50 (Pubitemid 46002344)
104. Franchini M. Rituximab in the treatment of adult acquired hemophilia A: a systematic review. Crit Rev Oncol Hematol: 2007; 63 1 47 52 (Pubitemid 46824066)
105. Aggarwal A., Grewal R., Green R. J., et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia: 2005; 11 1 13 19 (Pubitemid 40253762)
106. Castaman G., Tosetto A. Is a reduced intensity treatment with rituximab effective in acquired haemophilia A? Haemophilia: 2011; 17 5 817 818
107. Coppola A., Di Minno M. ND, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol: 2010; 150 5 515 528
108. Green D. Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood: 1971; 37 4 381 387
109. Nemes L., Pitlik E. New protocol for immune tolerance induction in acquired hemophilia. Haematologica: 2000; 85 10 64 68